A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy
A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy
ClinicalTrials.gov ID: NCT05878561
Sponsor: Boryung Pharmaceutical Co., Ltd
Information provided by: Boryung Pharmaceutical Co., Ltd (Responsible Party)
Last Update Posted: 2023-05-26
Brief Summary:
The objective of this clinical trial is to evaluate the efficacy and safety of BR1015 Combination therapy group in comparison with Fimasartan monotherapy group at Week 8 for essential hypertension patients who do not adequately responded by Fimasartan 30 mg
Official Title:
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy in Comparison With Fimasartan Monotherapy for Essential Hypertension Patients Not Adequately Responded by Fimasartan 30 mg
Intervention / Treatment:
- Drug: Fimasartan + Indapamide
- Drug: Fimasartan + Indapamide placebo
| Category | Value |
|---|---|
| Study Start (Actual) | 2022-11-09 |
| Primary Completion (Estimated) | 2024-10 |
| Study Completion (Estimated) | 2024-10 |
| Enrollment (Estimated) | 244 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
BR-FIC-CT-301 |